Doctor versus AI for timing the IVF egg maturation trigger
Ovarian Stimulation Outcomes During a GnRH Antagonist Protocol for In-vitro Fertilization When Comparing Trigger Day Decision by Physicians Versus an Artificial Intelligence-based Algorithm - A Randomized Control Study.
This test sees if using an AI algorithm instead of a doctor to choose the trigger day produces more mature eggs during a GnRH-antagonist IVF stimulation.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 180 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | All |
| Sponsor | FertilAI Industry-sponsored |
| Locations | 1 site (Herzliya) |
| Trial ID | NCT07110285 on ClinicalTrials.gov |
What this trial studies
This interventional study compares the number of mature oocytes retrieved from ovarian stimulation cycles using a GnRH antagonist when trigger-day decisions are made by treating physicians versus an artificial intelligence algorithm. Eligible participants are patients undergoing stimulation for oocyte cryopreservation or for fertilization via ICSI where oocytes are denuded and maturity can be assessed. Cycles follow standard antagonist protocols and maturity is measured after oocyte denudation, with the primary outcome being the count of mature oocytes. The trial is sponsored by FertilAI and conducted at Herzliya Medical Center.
Who should consider this trial
Good fit: People undergoing ovarian stimulation with a GnRH antagonist for egg freezing or for IVF with ICSI where oocytes will be denuded and maturity recorded are ideal candidates.
Not a fit: Patients using non-antagonist stimulation protocols, those whose oocytes are not denuded so maturity cannot be assessed, or patients who withdraw from follow-up are unlikely to benefit.
Why it matters
Potential benefit: If successful, the approach could increase the number of mature oocytes collected, potentially improving IVF or fertility preservation outcomes.
How similar studies have performed: AI tools have shown promise in embryo selection and cycle predictions, but using AI specifically to time the trigger day is relatively new with limited published evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients undergoing an ovarian stimulation cycle utilizing the GnRH antagonist protocol for oocyte cryopreservation or for fertilization via intracytoplasmic sperm injection (ICSI) (any treatment where oocytes are denuded and maturity may be assessed). Exclusion Criteria: * Loss to follow-up, patient retracts consent to participate
Where this trial is running
Herzliya
- Herzliya Medical Center — Herzliya, Israel (Recruiting)
Study contacts
- Principal investigator: Ariel Hourvitz, MD — Herzeliya Medical Center, Israel
- Study coordinator: Michal Youngster, MD
- Email: michalyo@gmail.com
- Phone: +972-50-643-0111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.